Biotech drama Monday: Biogen's Alzheimer's drug, aducanumab, failed in clinical trials (like every other anti-a-beta drug, and basically every other drug for Alzheimer's). Biogen claimed they re-analyzed the data & actually the drug did work. They are now filing for FDA approval
-
Show this thread
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.